-
Kenya's economy faces climate change risks: World Bank
-
Qantas to launch non-stop Sydney-London flights in October 2027
-
US Fed chair Warsh vows reforms as central bank signals rate hikes on horizon
-
US Federal Reserve holds rates steady, raises inflation expectations
-
Brest boss Roy dies aged 58 from cancer
-
Military salutes and K-pop madness shake up Colombia campaigning
-
Recovery of ship traffic in Hormuz limited, but signs emerge
-
England's World Cup opener puts Spanish resort on beer alert
-
Nations allege 'attacks' on science at key climate talks
-
Plague was killing hunter-gatherers 5,500 years ago: study
-
Prince Harry and family to visit UK in July: media
-
What happens when the Strait of Hormuz re-opens?
-
US retail sales beat expectations in May as energy costs stay high
-
Spain logs third-warmest year on record in 2025
-
'Heartbreaking': Afghan govt staff abandon smartphones
-
Groundbreaking US astronaut Christina Koch wins top Spanish award
-
BBC eyes compulsory redundancies in cost-cutting drive
-
Sovereignty fears dog AI enthusiasm at France's Vivatech
-
Japan puts the heat on suspected ice cream cartel
-
Sovereignty fears to dog AI enthusiasm at France's Vivatech
-
MEXC May Report: SPACEX Launchpad Oversubscribed 15.5x, US Equity Futures Volume Jumps 85%
-
MEXC Prediction Markets Launches Combo to Enable Multi-Event Combination Trading
-
'We have always won': Ebola pioneer still on front line at 84
-
Trap, neuter, release: Jakarta battles cat-astrophic stray numbers
-
US Fed set to hold rates steady at Warsh's first meeting in charge
-
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA
-
Spanish actor Javier Bardem leaves his mark on Hollywood Boulevard
-
After three sessions, SpaceX already among world's most valuable companies
-
Surging SpaceX overtakes Amazon to become 5th biggest company
-
BMW downgrades 2026 targets on Mideast war, China woes
-
German court bans McDonald's from making climate claim
-
Campaigners urge G7 chiefs to protect children from AI risks
-
Like father, like son: Prince George to attend Eton College
-
Paris store to part ways with Shein after ownership change
-
US Federal Reserve kicks off first meeting with Warsh as chair
-
How can France-UK mission help reopen Strait of Hormuz?
-
EU to ban plant-based 'steaks' but veggie 'burgers' sizzle on
-
Russian oil producer rations fuel as Ukraine attacks bite
-
EU clears major hurdle on US tariff deal
-
Mideast war peace deal boosts German investor morale
-
Iran says talks on final US deal to begin this week
-
With feasts and music, Kashmiri weddings keep traditions alive
-
French spies drop AI giant Palantir over US overreliance fears
-
India blocks Telegram before retest exam to curb cheating
-
Bank of Japan hikes interest rate to 31-year high
-
Stocks extend rally, oil flat as peace optimism builds
-
Deadline looms for UniCredit's hostile bid for Commerzbank
-
Bank of Japan hikes rate to 31-year high
-
Scientist confronting the rising global threat of mosquitoes
-
India eyes biofertilisers after Mideast war stoked supply fears
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
J.Bondarev--CPN